Introduction
Professor Zhang Jian (张剑) is a Professor of Medical Oncology at Fudan University Shanghai Cancer Center (FUSCC) — one of China's most prestigious and highest-volume cancer centers. Professor Zhang is recognized as one of Shanghai's leading breast cancer medical oncologists, with particular expertise in hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitor therapy, endocrine therapy optimization, and metastatic breast cancer management. Working within FUSCC's world-class breast cancer medical oncology team alongside Chief Professor Hu Xichun, Professor Zhang has established himself as a leading expert in HR+ breast cancer systemic treatment. His expertise spans the full spectrum of HR+ breast cancer management, with particular distinction in CDK4/6 inhibitor combinations, endocrine resistance mechanisms, and novel targeted agents for metastatic HR+ breast cancer. International patients with HR+ breast cancer consistently regard Professor Zhang as a premier choice at FUSCC.
Academic Distinctions & Leadership
- Professor of Medical Oncology, Fudan University Shanghai Cancer Center (FUSCC)
- Member, Chinese Society of Clinical Oncology (CSCO)
- Breast Cancer Committee Member, CSCO
- Member, Chinese Anti-Cancer Association, Breast Cancer Committee
- Editorial Board Member, multiple Chinese oncology journals
- Recipient, multiple Shanghai municipal and national science and technology awards
- Visiting fellow at leading breast cancer centers internationally
Specializations & Expertise
Hormone Receptor-Positive Breast Cancer
- CDK4/6 inhibitor combinations (palbociclib, ribociclib, abemaciclib + endocrine therapy)
- Aromatase inhibitor therapy (letrozole, anastrozole, exemestane)
- Fulvestrant for metastatic HR+ breast cancer
- Ovarian suppression for premenopausal HR+ breast cancer
- Extended adjuvant endocrine therapy
- Endocrine therapy sequencing for metastatic disease
Endocrine Resistance Management
- ESR1 mutation detection and management (elacestrant)
- PIK3CA mutation management (alpelisib + fulvestrant)
- AKT pathway inhibitors (capivasertib)
- mTOR inhibitors (everolimus + exemestane)
- CDK4/6 inhibitor resistance mechanisms and post-progression strategies
Neoadjuvant & Adjuvant Therapy
- Neoadjuvant chemotherapy for HR+ breast cancer
- Neoadjuvant endocrine therapy for postmenopausal HR+ breast cancer
- Adjuvant CDK4/6 inhibitor therapy (abemaciclib for high-risk HR+ breast cancer)
- Adjuvant endocrine therapy optimization
- Bone-modifying agents (bisphosphonates, denosumab) for adjuvant therapy
Metastatic Breast Cancer
- First and subsequent line therapy for metastatic HR+ breast cancer
- Bone metastases management
- Visceral metastases management
- Brain metastases management
- Oligometastatic disease management
- Clinical trial access for novel agents
Other Breast Cancer Subtypes
- HER2-positive breast cancer management
- Triple-negative breast cancer management
- Male breast cancer management
- Breast cancer in young women
- Hereditary breast cancer (BRCA1/2) management
Clinical Excellence & Innovation
- CDK4/6 Inhibitor Expert: Extensive experience with palbociclib, ribociclib, and abemaciclib combinations for HR+ breast cancer, achieving significant improvements in progression-free survival
- Endocrine Resistance Expert: Expert in identifying and managing endocrine resistance mechanisms including ESR1 mutations and PIK3CA mutations
- Premenopausal Breast Cancer: Specialized expertise in managing premenopausal HR+ breast cancer with ovarian suppression and CDK4/6 inhibitors
- Novel Agent Access: Active participation in clinical trials of novel HR+ breast cancer agents at FUSCC
- Bone Metastases Management: Comprehensive bone metastases management integrating systemic therapy and bone-modifying agents
Research & Academic Contributions
Professor Zhang is an active researcher with peer-reviewed publications in leading Chinese and international oncology journals. His research focuses on CDK4/6 inhibitor therapy, endocrine resistance mechanisms, ESR1 mutations, and novel targeted agents for HR+ metastatic breast cancer.
Hospital Affiliation
Fudan University Shanghai Cancer Center (FUSCC)
270 Dongan Road, Xuhui District, Shanghai 200032
FUSCC is one of China's most prestigious cancer centers, featuring:
- One of China's highest-volume breast cancer programs
- Comprehensive breast cancer MDT
- Advanced molecular profiling (ESR1, PIK3CA, BRCA, NGS)
- Clinical trial access for novel breast cancer agents
- International patient services with English-speaking coordinators
Why Choose Professor Zhang Jian?
- HR+ Breast Cancer Expert: Comprehensive CDK4/6 inhibitor and endocrine therapy expertise
- Endocrine Resistance Specialist: Expert in ESR1, PIK3CA, and AKT pathway resistance management
- Premenopausal Breast Cancer: Specialized expertise in young women with HR+ breast cancer
- Clinical Trial Access: Novel agent access through FUSCC clinical trials
- Cost-Effective Excellence: Breast cancer treatment costs in Shanghai are typically 60-80% lower than in the US or Europe
- Proven International Track Record: Trusted by patients from around the world
Conditions Treated
- Hormone receptor-positive breast cancer (early and metastatic)
- Premenopausal HR+ breast cancer
- CDK4/6 inhibitor-resistant HR+ breast cancer
- ESR1-mutated metastatic breast cancer
- PIK3CA-mutated HR+ breast cancer
- HR+ breast cancer with bone metastases
- Male breast cancer
- Hereditary (BRCA) breast cancer
International Patient Services
China Medical Concierge - Shanghai (CMCS) provides comprehensive support for international patients seeking breast cancer medical oncology care with Professor Zhang Jian at FUSCC.
Pre-Arrival Support
- Medical Record Review: Review of your pathology, ER/PR/HER2 status, ESR1/PIK3CA mutation status, staging CT/bone scan, and prior treatment history
- Virtual Consultation: Video consultation with Professor Zhang's team
- MDT Review: Arrangement of multidisciplinary breast cancer team review
- Treatment Planning: Personalized endocrine therapy and CDK4/6 inhibitor plan
- Cost Transparency: Detailed cost estimate
- Visa Assistance: Medical visa guidance and invitation letters
- Travel Arrangements: Flights, airport pickup, and accommodation near the hospital
During Treatment
- Professional Medical Interpretation: Experienced oncology interpreters at all appointments
- Hospital Navigation Support: Registration, payment, and hospital navigation assistance
- 24/7 Support: Round-the-clock assistance for any concerns
Post-Treatment Care
- Report Translation: Complete translation of all pathology and treatment reports
- Treatment Summary: Comprehensive oncology summary for your home oncologist
- Medication Guide: Detailed CDK4/6 inhibitor and endocrine therapy instructions
- Telemedicine Follow-up: Virtual follow-up with Professor Zhang's team
- Long-term Support: Ongoing assistance after returning home
Schedule Your Consultation
If you or a loved one has hormone receptor-positive breast cancer and is seeking expert CDK4/6 inhibitor therapy or endocrine resistance management, Professor Zhang Jian at Fudan University Shanghai Cancer Center offers world-class expertise at a fraction of Western costs.
Contact China Medical Concierge - Shanghai today to request a pathology and staging review, schedule a virtual consultation, and begin planning your journey to Shanghai for expert breast cancer care.
Bridging international patients with Shanghai's finest breast cancer oncologists — because your HR+ breast cancer care deserves the latest in endocrine therapy and targeted treatment.
0 Kommentare